Skip to content
    BVF Partners L.P. logo

    BVF Partners L.P.

    San Francisco, California, United StatesFounded 1993
    bvflp.com
    Biotech & Life SciencesHealthcare

    BVF Partners L.P. is a San Francisco-based private investment partnership founded in 1993 by Mark N. Lampert, specializing in fundamentally-driven investments in small- to mid-cap biotechnology and pharmaceutical companies. The firm employs an active, research-based engagement approach across both private and public biotech investments.

    63% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 6 prior). Their most common stage is series-b (41% of deals). Average disclosed round size is $145.7M (across 39 rounds with reported amounts).

    Find people at BVF Partners L.P. on Goldilocks AI

    Portfolio

    39

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    2

    Team

    MM

    Michael Murray

    Managing Director

    SL

    Spike Loy

    Managing Director

    TN

    Thor Nagel

    Biotech Investor

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    46 investments
    CompanyRoundAmountDate
    Ambrosia Biosciences Inc. logoAmbrosia Biosciences Inc.Series B$100MMar 2026
    Third Arc Bio logoThird Arc BioSeries A$52MFeb 2026
    Sagimet Biosciences logoSagimet BiosciencesSeries C$175MJan 2026
    Crescent Biopharma logoCrescent BiopharmaGrowth$200MJun 2025
    NNumab TherapeuticsSeries C$55MJan 2025
    RAPT Therapeutics logoRAPT TherapeuticsSeries D$150MDec 2024
    Elektrofi logoElektrofiSeries C$112.3MOct 2024
    AAlpha-9 Oncology, Inc.Series C$175MOct 2024
    Inventiva logoInventivaUnknown—Oct 2024
    Pheon Therapeutics logoPheon TherapeuticsSeries B$120MMay 2024
    AltruBio logoAltruBioSeries B$225MMay 2024
    Cidara Therapeutics logoCidara TherapeuticsUnknown$240MApr 2024
    Diagonal Therapeutics logoDiagonal TherapeuticsSeries A$128MApr 2024
    Aro Biotherapeutics logoAro BiotherapeuticsSeries B$41.5MNov 2023
    Forward Therapeutics logoForward TherapeuticsSeries A$50MNov 2023
    Alpha9Tx logoAlpha9TxSeries B$75MDec 2022
    Ventus logoVentusSeries C$140MFeb 2022
    Nimbus logoNimbusUnknown$125MJan 2022
    ShouTi logoShouTiSeries B$100MJan 2022
    Numab logoNumabSeries C—May 2021
    Ventus logoVentusSeries B$100MApr 2021
    TYRA Biosciences logoTYRA BiosciencesSeries B$106MMar 2021
    NNewAmsterdam PharmaSeries A—Jan 2021
    EQRx logoEQRxGrowth$1.8BJan 2021
    OOlema OncologySeries C$85MOct 2020
    Page 1 of 2

    Top Co-Investors

    RA Capital Management19 shared
    Cormorant Asset Management12 shared
    Alexandria Venture Investments10 shared
    Casdin Capital9 shared
    GV8 shared
    Andreessen Horowitz7 shared
    Perceptive Advisors7 shared
    Samsara BioCapital7 shared
    Pfizer Ventures7 shared
    Logos Capital6 shared
    Forbion6 shared
    Fonds de solidarité FTQ6 shared
    Versant Ventures6 shared
    OrbiMed5 shared
    Deep Track Capital5 shared
    New Enterprise Associates5 shared
    The Invus Group, LLC5 shared
    Foresite Capital4 shared
    Atlas Venture4 shared
    Nextech Invest Ltd.4 shared

    Last updated: 7 October 2026